NBC Los Angeles3h
FDA weighs in on diet drug shortage, creating more confusion about compounding
As millions patients struggled to fill their prescriptions for the new weight loss drugs, many have turned to compounded copies.
Here are 4 biotech stocks that could get a boost from a more open FDA regulatory climate
Biotech-stock investing has one tough test for success - and it's about to get easier ...
Biotech-stock investing has one tough test for success — and it’s about to get easier
Own stocks of companies that get drugs approved. That hasn’t been so easy. But the U.S. Food & Drug Administration (FDA) has ...
Aldeyra Therapeutics Shares Up, FDA to Review New Drug Application
Shares of Aldeyra Therapeutics gained after the Food and Drug Administration accepted the company's resubmitted new drug application for its treatment of dry eye disease for review. The stock rose 11% ...
Business Wire12h
Contineum Therapeutics Expands Clinical Development of PIPE-791 With FDA Authorization of Its Investigational New Drug (IND) Application for Chronic Pain
Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company), a clinical stage biopharmaceutical company focused on discovering and developi ...
Medicaid dominates coverage of Novo, Lilly weight-loss drugs
State Medicaid programs for low-income families are the single biggest source of coverage, giving 31.6 million people access ...
New Weight Loss Drug Boosts Energy and Reduces Appetite Without Side Effects
Researchers at the University of Copenhagen have identified a new drug target for weight loss that curbs appetite, boosts ...
Business Insider22h
Aldeyra Therapeutics Says FDA Accepts NDA For Reproxalap In Dry Eye Disease
has accepted for review the resubmitted New Drug Application (NDA) for topical ocular reproxalap, a first-in-class investigational new drug candidate, for the treatment of the signs and symptoms of ...
Business Insider23h
Aldeyra says FDA accepts reproxalap NDA, AbbVie deal expanded to $100M
announced that the U.S. Food and Drug Administration or FDA has accepted for review the resubmitted New Drug Application NDA for topical ocular reproxalap, a first-in-class investigational new drug ...
Cure Today2d
FDA Receives Application for Dato-DXd Treatment in EGFR-Mutated NSCLC
For patients with previously treated EGFR-mutated NSCLC, a new BLA has been submitted to the FDA seeking the accelerated ...
Targeted Oncology3d
FDA Approves IND for AS1986NS, a New Approach in Prostate Cancer Research
The FDA has approved the investigational new drug application of AS1986NS for prostate cancer detection and treatment.
Regeneron, Sanofi Get New FDA Review of Dupixent for CSU
The FDA last year turned away the companies' application and asked for additional efficacy data. Regeneron and Sanofi said the resubmission adds results from an additional Phase 3 study of Dupixent in ...